J. D'haese, K. Theunissen, and E. Vermeulen, Detection of galactomannan in bronchoalveolar 1053 lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: Analytical and 1054 clinical validity, Journal of clinical microbiology, vol.50, pp.1258-1263, 2012.

A. C. Pasqualotto, M. O. Xavier, and L. B. Sanchez, Diagnosis of invasive aspergillosis in lung 1056 transplant recipients by detection of galactomannan in the bronchoalveolar lavage fluid

, Transplantation, vol.90, pp.306-311, 2010.

M. L. Luong, C. J. Clancy, and A. Vadnerkar, Comparison of an aspergillus real-time polymerase 1059 chain reaction assay with galactomannan testing of bronchoalvelolar lavage fluid for the 1060 diagnosis of invasive pulmonary aspergillosis in lung transplant recipients, Clin Infect Dis, vol.1061, pp.1218-1226, 2011.

W. Meersseman, K. Lagrou, and J. Maertens, Galactomannan in bronchoalveolar lavage fluid: 1063 A tool for diagnosing aspergillosis in intensive care unit patients, Am J Respir Crit Care Med, vol.1064, pp.27-34, 2008.

D. E. Karageorgopoulos, E. K. Vouloumanou, F. Ntziora, A. Michalopoulos, and P. I. Rafailidis, Falagas 1066 ME. ß-d-glucan assay for the diagnosis of invasive fungal infections: A meta-analysis, Clin 1067 Infect Dis, vol.52, pp.750-770, 2011.

J. Prattes, M. Lackner, and S. Eigl, Diagnostic accuracy of the aspergillus -specific 1069 bronchoalveolar lavage lateral-flow assay in haematological malignancy patients, Mycoses, vol.1070, pp.461-469, 2015.

T. Boch, M. Reinwald, and P. Postina, Identification of invasive fungal diseases in 1072 immunocompromised patients by combining an aspergillus specific pcr with a multifungal 1073 DNA-microarray from primary clinical samples, Mycoses, vol.58, pp.735-745, 2015.

T. Boch, B. Spiess, and O. A. Cornely, Diagnosis of invasive fungal infections in haematological 1075 patients by combined use of galactomannan, 1,3-beta-d-glucan, aspergillus pcr, multifungal 1076 DNA-microarray, and aspergillus azole resistance pcrs in blood and bronchoalveolar lavage 1077 samples: Results of a prospective multicentre study, Clin Microbiol Infect, 2016.

J. Springer, C. O. Morton, and M. Perry, Multicenter comparison of serum and whole-blood 1079 specimens for detection of aspergillus DNA in high-risk hematological patients, Journal of 1080 clinical microbiology, vol.51, pp.1445-1450, 2013.

L. Pagano, M. Caira, and A. Nosari, The use and efficacy of empirical versus pre-emptive 1334 therapy in the management of fungal infections: The hema e-chart project, Haematologica, vol.1335, pp.1366-1370, 2011.

T. J. Walsh, H. Teppler, and G. R. Donowitz, Caspofungin versus liposomal amphotericin b for 1337 empirical antifungal therapy in patients with persistent fever and neutropenia, N Engl J Med, vol.1338, pp.1391-1402, 2004.

T. J. Walsh, R. W. Finberg, and C. Arndt, Liposomal amphotericin b for empirical therapy in 1340 patients with persistent fever and neutropenia. National institute of allergy and infectious 1341 diseases mycoses study group, N Engl J Med, vol.340, pp.764-771, 1999.

T. J. Walsh, P. Pappas, and D. J. Winston, Voriconazole compared with liposomal amphotericin b 1343 for empirical antifungal therapy in patients with neutropenia and persistent fever, N Engl J, p.1344

. Med, , vol.346, pp.225-234, 2002.

P. L. White, C. Parr, C. Thornton, and R. A. Barnes, Evaluation of real-time pcr, galactomannan 1346 enzyme-linked immunosorbent assay (elisa), and a novel lateral-flow device for diagnosis of 1347 invasive aspergillosis, Journal of clinical microbiology, vol.51, pp.1510-1516, 2013.

P. L. White, J. R. Wingard, and S. Bretagne, Aspergillus polymerase chain reaction: Systematic 1349 review of evidence for clinical use in comparison with antigen testing, Clin Infect Dis, vol.61, pp.1293-1303, 1350.

B. Liss, O. A. Cornely, D. Hoffmann, V. Dimitriou, and H. Wisplinghoff, 3-beta-d-glucan 1352 contamination of common antimicrobials-authors' response, J Antimicrob Chemother, vol.1, pp.2997-2999, 1353.

B. Liss, O. A. Cornely, D. Hoffmann, V. Dimitriou, and H. Wisplinghoff, 3-beta-d-glucan 1355 contamination of common antimicrobials, J Antimicrob Chemother, vol.1, pp.913-915, 2016.

B. Liss, O. A. Cornely, D. Hoffmann, V. Dimitriou, and H. Wisplinghoff, 3-ß-d-glucan concentrations in 1357 blood products predict false positive post-transfusion results, Mycoses, vol.1, pp.39-42, 2016.

H. Hammarstrom, N. Kondori, V. Friman, and C. Wenneras, How to interpret serum levels of beta-1359 glucan for the diagnosis of invasive fungal infections in adult high-risk hematology patients: 1360 Optimal cut-off levels and confounding factors, Eur J Clin Microbiol Infect Dis, vol.34, pp.917-1361, 2015.

P. Tabarsi, A. Soraghi, and M. Marjani, Comparison of serum and bronchoalveolar lavage 1906 galactomannan in diagnosing invasive aspergillosis in solid-organ transplant recipients, Clin Transplant, vol.10, pp.278-281, 1907.

N. Guigue, J. Menotti, and P. Ribaud, False positive galactomannan test after ice-pop ingestion, 1909.

, Engl J Med, vol.369, pp.97-98, 2013.

R. Petraitiene, V. Petraitis, and J. R. Witt, Galactomannan antigenemia after infusion of 1911 gluconate-containing plasma-lyte, Journal of clinical microbiology, vol.49, pp.4330-4332, 2011.

P. Martin-rabadan, P. Gijon, A. Fernandez, R. Ballesteros, M. Anguita et al., False-1913 positive aspergillus antigenemia due to blood product conditioning fluids, Clin Infect Dis, vol.55, pp.22-27, 1914.

M. Mikulska, E. Furfaro, D. Bono, and V. , Piperacillin/tazobactam (tazocintm) seems to be no 1916 longer responsible for false-positive results of the galactomannan assay, J Antimicrob, 1917.

, Chemother, vol.67, pp.1746-1748, 2012.

P. Vergidis, R. C. Walker, and D. R. Kaul, False-positive aspergillus galactomannan assay in solid 1919 organ transplant recipients with histoplasmosis, Transpl Infect Dis, vol.14, pp.213-217, 2012.

Y. T. Huang, C. C. Hung, C. H. Liao, H. Y. Sun, S. C. Chang et al., Detection of circulating 1921 galactomannan in serum samples for diagnosis of penicillium marneffei infection and 1922 cryptococcosis among patients infected with human immunodeficiency virus, Journal of 1923 clinical microbiology, vol.45, pp.2858-2862, 2007.

M. Nucci, F. Carlesse, and P. Cappellano, Earlier diagnosis of invasive fusariosis with 1925 aspergillus serum galactomannan testing, PLoS One, vol.9, p.87784, 2014.

S. T. King and K. R. Stover, Considering confounders of the galactomannan index: The role of 1927 piperacillin-tazobactam, Clin Infect Dis, vol.58, pp.751-752, 2014.

L. Y. Chai, B. J. Kullberg, and E. M. Johnson, Early serum galactomannan trend as a predictor of 1929 outcome of invasive aspergillosis, Journal of clinical microbiology, vol.50, pp.2330-2336, 2012.

M. L. Luong, C. J. Clancy, and A. Vadnerkar, Comparison of an aspergillus real-time polymerase 1931 chain reaction assay with galactomannan testing of bronchoalvelolar lavage fluid for the 1932 diagnosis of invasive pulmonary aspergillosis in lung transplant recipients, Clin Infect Dis, vol.52, pp.1218-1226, 1933.

M. Reinwald, B. Spiess, and W. J. Heinz, Diagnosing pulmonary aspergillosis in patients with 1935 hematological malignancies: A multicenter prospective evaluation of an aspergillus pcr 1936 assay and a galactomannan elisa in bronchoalveolar lavage sample, Eur J Haematol, vol.89, pp.120-127, 1937.

S. C. Heng, O. Morrissey, and S. C. Chen, Utility of bronchoalveolar lavage fluid galactomannan 1939 alone or in combination with pcr for the diagnosis of invasive aspergillosis in adult 1940 hematology patients: A systematic review and meta-analysis, Crit Rev Microbiol, vol.41, p.1941, 2015.

M. Zou, L. Tang, and S. Zhao, Systematic review and meta-analysis of detecting 1943 galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis, PLoS, vol.7, p.43347, 1944.

C. E. Fisher, A. M. Stevens, W. Leisenring, S. A. Pergam, M. Boeckh et al., The serum 1946 galactomannan index predicts mortality in hematopoietic stem cell transplant recipients with 1947 invasive aspergillosis, Clin Infect Dis, vol.57, pp.1001-1004, 2013.

P. E. Verweij, K. Brinkman, H. P. Kremer, B. J. Kullberg, and J. F. Meis, Aspergillus meningitis: Diagnosis by 1949 non-culture-based microbiological methods and management, Journal of clinical 1950 microbiology, vol.37, pp.1186-1189, 1999.

C. Viscoli, M. Machetti, and P. Gazzola, Aspergillus galactomannan antigen in the 1952 cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis, Journal of clinical microbiology, vol.40, pp.1496-1499, 1953.

R. R. Klont, M. A. Mennink-kersten, and P. E. Verweij, Utility of aspergillus antigen detection in 1955 specimens other than serum specimens, Clin Infect Dis, vol.39, pp.1467-1474, 2004.

Y. Lu, Y. Q. Chen, Y. L. Guo, S. M. Qin, C. Wu et al., Diagnosis of invasive fungal disease using 1957 serum (1-3)-ß-d-glucan: A bivariate meta-analysis, Intern Med, vol.50, pp.2783-2791, 2011.

F. Lamoth, M. Cruciani, and C. Mengoli, ß-glucan antigenemia assay for the diagnosis of 1959 invasive fungal infections in patients with hematological malignancies: A systematic review 1960 and meta-analysis of cohort studies from the third european conference on infections in 1961 leukemia (ecil-3), Clin Infect Dis, vol.54, pp.633-643, 2012.

L. Senn, J. O. Robinson, and S. Schmidt, 1,3-beta-d-glucan antigenemia for early diagnosis of 1963 invasive fungal infections in neutropenic patients with acute leukemia, Clin Infect Dis, vol.46, pp.878-885, 1964.

M. Ellis, B. Al-ramadi, and M. Finkelman, Assessment of the clinical utility of serial beta-d-1966 glucan concentrations in patients with persistent neutropenic fever, J Med Microbiol, vol.57, pp.287-295, 1967.

M. Kawazu, Y. Kanda, and Y. Nannya, Prospective comparison of the diagnostic potential of 1969 real-time pcr, double-sandwich enzyme-linked immunosorbent assay for galactomannan, 1970 145 and a (1-->3)-beta-d-glucan test in weekly screening for invasive aspergillosis in patients with 1971 hematological disorders, Journal of clinical microbiology, vol.42, pp.2733-2741, 2004.

Z. Odabasi, G. Mattiuzzi, and E. Estey, Beta-d-glucan as a diagnostic adjunct for invasive fungal 1973 infections: Validation, cutoff development, and performance in patients with acute 1974 myelogenous leukemia and myelodysplastic syndrome, Clin Infect Dis, vol.39, pp.199-205, 2004.

L. Ostrosky-zeichner, A. Bd, and D. H. Kett, Multicenter clinical evaluation of the, pp.1-1976

, >3) beta-d-glucan assay as an aid to diagnosis of fungal infections in humans, Clin Infect Dis, vol.41, pp.654-659, 1977.

D. Vlieger, G. Lagrou, K. Maertens, J. Verbeken, E. Meersseman et al., Beta-d-1979 glucan detection as a diagnostic test for invasive aspergillosis in immunocompromised 1980 critically ill patients with symptoms of respiratory infection: An autopsy-based study, Journal 1981 of clinical microbiology, vol.49, pp.3783-3787, 2011.

D. Bono, V. Delfino, E. Furfaro, and E. , Clinical performance of the (1,3)-beta-d-glucan assay 1983 in early diagnosis of nosocomial candida bloodstream infections, Clin Vaccine Immunol, vol.18, pp.2113-2117, 1984.

J. Acosta, M. Catalan, and A. Del-palacio-pérez-medel, Prospective study in critically ill non-1986 neutropenic patients: Diagnostic potential of (1,3)-ß-d-glucan assay and circulating 1987 galactomannan for the diagnosis of invasive fungal disease, Eur J Clin Microbiol Infect Dis, vol.31, pp.721-731, 1988.

M. Hoenigl, C. Koidl, and W. Duettmann, Bronchoalveolar lavage lateral-flow device test for 1990 invasive pulmonary aspergillosis diagnosis in haematological malignancy and solid organ 1991 transplant patients, J Infect, vol.65, pp.588-591, 2012.

J. Held, T. Schmidt, C. R. Thornton, E. Kotter, and H. Bertz, Comparison of a novel aspergillus lateral-1993 flow device and the platelia© galactomannan assay for the diagnosis of invasive aspergillosis 1994 following haematopoietic stem cell transplantation, Infection, vol.41, pp.1163-1169, 2013.

M. Hoenigl, J. Prattes, and B. Spiess, Performance of galactomannan, beta-d-glucan, 1996 aspergillus lateral-flow device, conventional culture, and pcr tests with bronchoalveolar 1997 lavage fluid for diagnosis of invasive pulmonary aspergillosis, Journal of clinical microbiology, vol.52, pp.2039-2045, 1998.

H. Einsele, K. Quabeck, and K. D. Müller, Prediction of invasive pulmonary aspergillosis from 2000 colonisation of lower respiratory tract before marrow transplantation, Lancet, vol.352, 1998.

C. M. Tang, D. W. Holden, A. Aufauvre-brown, and J. Cohen, The detection of aspergillus spp. By the 2003 polymerase chain reaction and its evaluation in bronchoalveolar lavage fluid, Am Rev Respir, 2004.

, Dis, vol.148, pp.1313-1317, 1993.

P. E. Verweij, J. P. Latge, and A. J. Rijs, Comparison of antigen detection and pcr assay using 2006 bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients 2007 receiving treatment for hematological malignancies, Journal of clinical microbiology, vol.33, pp.3150-3153, 1995.

S. Bretagne, J. M. Costa, and A. Marmorat-khuong, Detection of aspergillus species DNA in 2010 bronchoalveolar lavage samples by competitive pcr, Journal of clinical microbiology, vol.33, pp.1164-1168, 1995.

M. E. Jones, A. J. Fox, and A. J. Barnes, Pcr-elisa for the early diagnosis of invasive pulmonary 2013 aspergillus infection in neutropenic patients, J Clin Pathol, vol.51, pp.652-656, 1998.

H. Skladny, D. Buchheidt, and C. Baust, Specific detection of aspergillus species in blood and 2015 bronchoalveolar lavage samples of immunocompromised patients by two-step pcr, Journal of 2016 clinical microbiology, vol.37, pp.3865-3871, 1999.

D. Buchheidt, C. Baust, and H. Skladny, Detection of aspergillus species in blood and 2018 bronchoalveolar lavage samples from immunocompromised patients by means of 2-step 2019 polymerase chain reaction: Clinical results, Clin Infect Dis, vol.33, pp.428-435, 2001.

M. P. Hayette, D. Vaira, and F. Susin, Detection of aspergillus species DNA by pcr in 2021 bronchoalveolar lavage fluid, Journal of clinical microbiology, vol.39, pp.2338-2340, 2001.

W. J. Melchers, P. E. Verweij, and P. Van-den-hurk, General primer-mediated pcr for detection of 2023 aspergillus species, Journal of clinical microbiology, vol.32, pp.1710-1717, 1994.

D. Buchheidt, C. Baust, H. Skladny, M. Baldus, S. Bräuninger et al., Clinical evaluation of a 2025 polymerase chain reaction assay to detect aspergillus species in bronchoalveolar lavage 2026 samples of neutropenic patients, Br J Haematol, vol.116, pp.803-811, 2002.

I. Raad, H. Hanna, A. Huaringa, D. Sumoza, R. Hachem et al., Diagnosis of invasive 2028 pulmonary aspergillosis using polymerase chain reaction-based detection of aspergillus in 2029 bal, Chest, vol.121, pp.1171-1176, 2002.

B. Spiess, D. Buchheidt, and C. Baust, Development of a lightcycler pcr assay for detection and 2031 quantification of aspergillus fumigatus DNA in clinical samples from neutropenic patients, Journal of clinical microbiology, vol.41, pp.1811-1818, 2003.

J. Meltiadis, W. J. Melchers, J. F. Meis, P. Van-den-hurk, G. Jannes et al., Evaluation of a 2034 polymerase chain reaction reverse hybridization line probe assay for the detection and 2035 identification of medically important fungi in bronchoalveolar lavage fluids, Medical 2036 mycology, vol.41, pp.65-74, 2003.

M. Sanguinetti, B. Posteraro, and L. Pagano, Comparison of real-time pcr, conventional pcr, 2038 and galactomannan antigen detection by enzyme-linked immunosorbent assay using 2039 bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive 2040 pulmonary aspergillosis, Journal of clinical microbiology, vol.41, pp.3922-3925, 2003.

K. Rantakokko-jalava, S. Laaksonen, and J. Issakainen, Semiquantitative detection by real-time 2042 pcr of aspergillus fumigatus in bronchoalveolar lavage fluids and tissue biopsy specimens 2043 from patients with invasive aspergillosis, Journal of clinical microbiology, vol.41, pp.4304-2044, 2003.

C. Lass-flörl, E. Gunsilius, and G. Gastl, Diagnosing invasive aspergillosis during antifungal 2046 therapy by pcr analysis of blood samples, Journal of clinical microbiology, vol.42, pp.4154-2047, 2004.

B. Musher, D. Fredricks, W. Leisenring, S. A. Balajee, C. Smith et al., Aspergillus 2049 galactomannan enzyme immunoassay and quantitative pcr for diagnosis of invasive 2050 aspergillosis with bronchoalveolar lavage fluid, Journal of clinical microbiology, vol.42, pp.2051-5517, 2004.

P. D. Khot, D. L. Ko, R. C. Hackman, and D. N. Fredricks, Development and optimization of quantitative 2053 pcr for the diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid, BMC Infect, p.2054

, Dis, vol.8, p.73, 2008.

E. Fréalle, K. Decrucq, and F. Botterel, Diagnosis of invasive aspergillosis using 2056 bronchoalveolar lavage in haematology patients: Influence of bronchoalveolar lavage human 2057 DNA content on real-time pcr performance, Eur J Clin Microbiol Infect Dis, vol.28, pp.223-232, 2009.

R. Torelli, M. Sanguinetti, and A. Moody, Diagnosis of invasive aspergillosis by a commercial 2059 real-time pcr assay for aspergillus DNA in bronchoalveolar lavage fluid samples from high-2060 risk patients compared to a galactomannan enzyme immunoassay, Journal of clinical 2061 microbiology, vol.49, pp.4273-4278, 2011.

M. Buess, G. Cathomas, and J. Halter, Aspergillus-pcr in bronchoalveolar lavage for detection 2063 of invasive pulmonary aspergillosis in immunocompromised patients, BMC Infect Dis, vol.12, p.237, 2012.

M. Reinwald, M. Hummel, and E. Kovalevskaya, Therapy with antifungals decreases the 2066 diagnostic performance of pcr for diagnosing invasive aspergillosis in bronchoalveolar lavage 2067 samples of patients with haematological malignancies, J Antimicrob Chemother, vol.67, pp.2068-2260, 2012.

C. F. Orsi, W. Gennari, and C. Venturelli, Performance of 2 commercial real-time polymerase 2070 chain reaction assays for the detection of aspergillus and pneumocystis DNA in 2071 bronchoalveolar lavage fluid samples from critical care patients, Diagn Microbiol Infect Dis, vol.73, pp.138-143, 2012.

J. Guinea, C. Padilla, and P. Escribano, Evaluation of mycassayt aspergillus for diagnosis of 2074 invasive pulmonary aspergillosis in patients without hematological cancer, PLoS One, vol.8, 2013.

J. Steinmann, J. Buer, P. M. Rath, A. Paul, and F. Saner, Invasive aspergillosis in two liver transplant 2077 recipients: Diagnosis by septifast, Transpl Infect Dis, vol.11, pp.175-178, 2009.

H. Komatsu, T. Fujisawa, and A. Inui, Molecular diagnosis of cerebral aspergillosis by sequence 2079 analysis with panfungal polymerase chain reaction, J Pediatr Hematol Oncol, vol.26, pp.40-44, 2004.

M. Kami, I. Shirouzu, and K. Mitani, Early diagnosis of central nervous system aspergillosis 2081 with combination use of cerebral diffusion-weighted echo-planar magnetic resonance image 2082 and polymerase chain reaction of cerebrospinal fluid, Intern Med, vol.38, pp.45-48, 1999.

M. Hummel, B. Spiess, and K. Kentouche, Detection of aspergillus DNA in cerebrospinal fluid 2084 from patients with cerebral aspergillosis by a nested pcr assay, Journal of clinical 2085 microbiology, vol.44, pp.3989-3993, 2006.

P. Badiee and A. Alborzi, Assessment of a real-time pcr method to detect human non-cryptococcal 2087 fungal meningitis, Arch Iran Med, vol.14, pp.381-384, 2011.

C. Mengoli, M. Cruciani, R. A. Barnes, J. Loeffler, and J. P. Donnely, Use of pcr for diagnosis of invasive 2089 aspergillosis: Systematic review and meta-analysis, Lancet Infect Dis, vol.9, pp.89-96, 2009.

P. L. White, C. Mengoli, and S. Bretagne, Evaluation of aspergillus pcr protocols for testing 2091 serum specimens, Journal of clinical microbiology, vol.49, pp.3842-3848, 2011.

P. L. White, C. J. Linton, M. D. Perry, E. M. Johnson, and R. A. Barnes, The evolution and evaluation of a 2093 whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in 2094 hematology patients in a routine clinical setting, Clin Infect Dis, vol.42, pp.479-486, 2006.

C. Lass-flörl, W. Mutschlechner, and M. Aigner, Utility of pcr in diagnosis of invasive fungal 2096 infections: Real-life data from a multicenter study, Journal of clinical microbiology, vol.51, pp.2097-863, 2013.

P. J. Paterson, S. Seaton, J. Mclaughlin, and C. C. Kibbler, Development of molecular methods for the 2099 identification of aspergillus and emerging moulds in paraffin wax embedded tissue sections

, Mol Pathol, vol.56, pp.368-370, 2003.

P. J. Paterson, S. Seaton, and T. D. Mchugh, Validation and clinical application of molecular 2102 methods for the identification of molds in tissue, Clin Infect Dis, vol.42, pp.51-56, 2006.

M. Von-eiff, N. Roos, R. Schulten, M. Hesse, M. Zåhlsdorf et al., Pulmonary aspergillosis: 2104 Early diagnosis improves survival, Respiration, vol.62, pp.341-347, 1995.

R. Kappe and D. Rimek, Antibody detection in patients with invasive aspergillosis, Mycoses, vol.47, p.59, 2004.

A. Cornillet, C. Camus, and S. Nimubona, Comparison of epidemiological, clinical, and 2108 biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: A 6-2109 year survey, Clin Infect Dis, vol.43, pp.577-584, 2006.

M. Weig, M. Frosch, and K. Tintelnot, Use of recombinant mitogillin for improved 2111 serodiagnosis of aspergillus fumigatus -associated diseases, Journal of clinical microbiology, vol.2112, pp.1721-1730, 2001.

C. Du, J. R. Wingard, S. Cheng, M. H. Nguyen, and C. Clancy, Serum igg responses against aspergillus 2114 proteins before hematopoietic stem cell transplantation or chemotherapy identify patients 2115 who develop invasive aspergillosis. Biology of blood and marrow transplantation : journal of 2116 the American Society for Blood and Marrow Transplantation, vol.18, pp.1927-1934, 2012.

K. Holmberg, M. Berdischewsky, and L. S. Young, Serologic immunodiagnosis of of invasive 2118 aspergillosis. The Journal of infectious diseases, vol.141, pp.656-664, 1980.

E. Manso, M. Montillo, D. Sio, G. , D. 'amico et al., Value of antigen and 2120 antibody detection in the serological diagnosis of invasive aspergillosis in patients with 2121 hematological malignancies, Eur J Clin Microbiol Infect Dis, vol.13, pp.756-760, 1994.

S. K. Mishra, S. Falkenberg, and K. N. Masihi, Efficacy of enzyme-linked immunosorbent assay in 2123 serodiagnosis of aspergillosis, Journal of clinical microbiology, vol.17, pp.708-710, 1983.

R. Kappe, A. Schulze-berge, and H. G. Sonntag, Evaluation of eight antibody tests and one antigen 2125 test for the diagnosis of invasive aspergillosis, Mycoses, vol.39, pp.13-23, 1996.

M. G. Fraczek, M. Bromley, and A. Buied, The cdr1b efflux transporter is associated with non-2127 cyp51a-mediated itraconazole resistance in aspergillus fumigatus, J Antimicrob Chemother, vol.2128, pp.1486-1496, 2013.

A. Bueid, S. J. Howard, and C. B. Moore, Azole antifungal resistance in aspergillus fumigatus, J Antimicrob Chemother, vol.65, pp.2116-2118, 2008.

M. C. Arendrup, E. Mavridou, and K. L. Mortensen, Development of azole resistance in 2132 aspergillus fumigatus during azole therapy associated with change in virulence, PLoS ONE. 2133, vol.5, p.10080, 2010.

J. W. Van-der-linden, R. R. Jansen, and D. Bresters, Azole-resistant central nervous system 2135 aspergillosis, Clin Infect Dis, vol.48, pp.1111-1113, 2009.

H. Badali, A. Vaezi, and I. Haghani, Environmental study of azole-resistant aspergillus 2137 fumigatus with tr34/l98h mutations in the cyp51a gene in iran, Mycoses, vol.56, pp.659-663, 2013.

A. Chowdhary, S. Kathuria, and J. Xu, Clonal expansion and emergence of environmental 2139 multiple-triazole-resistant aspergillus fumigatus strains carrying the tr(3)(4)/l98h mutations 2140 in the cyp51a gene in india, PLoS ONE, vol.7, p.52871, 2012.

K. L. Mortensen, E. Mellado, C. Lass-florl, J. L. Rodriguez-tudela, H. K. Johansen et al.,

, Environmental study of azole-resistant aspergillus fumigatus and other aspergilli in austria, 2143 denmark, and spain, Antimicrob Agents Chemother, vol.54, pp.4545-4549, 2010.

M. C. Arendrup, M. Cuenca-estrella, C. Lass-florl, and W. W. Hope, Breakpoints for antifungal agents: 2145 An update from eucast focussing on echinocandins against candida spp. And triazoles against 2146 aspergillus spp, Drug Resist Updat, vol.16, pp.81-95, 2013.

E. Vermeulen, J. Maertens, H. Schoemans, and K. Lagrou, Azole-resistant aspergillus fumigatus due 2148 to tr46/y121f/t289a mutation emerging in belgium, Euro Surveill, vol.17, 2012.

A. Chowdhary, S. Kathuria, H. S. Randhawa, S. N. Gaur, C. H. Klaassen et al., Isolation of multiple-2150 triazole-resistant aspergillus fumigatus strains carrying the tr/l98h mutations in the cyp51a 2151 gene in india, J Antimicrob Chemother, vol.67, pp.362-366, 2012.

P. M. Rath, D. Buchheidt, B. Spiess, E. Arfanis, J. Buer et al., First reported case of azole-2153 resistant aspergillus fumigatus due to the tr/l98h mutation in germany, Antimicrob Agents, p.2154

, Chemother, vol.56, pp.6060-6061, 2012.

S. A. Balajee, J. W. Baddley, and S. W. Peterson, Aspergillus alabamensis, a new clinically relevant 2156 species in the section terrei, Eukaryot Cell, vol.8, pp.713-722, 2009.

J. B. Buil, H. Van-der-lee, and A. Rijs, Single-center evaluation of an agar-based screening for 2158 azole resistance in aspergillus fumigatus by using vipcheck, Antimicrob Agents Chemother, p.61, 2017.

C. Van-leer-buter, R. P. Takes, K. M. Hebeda, W. J. Melchers, and P. E. Verweij, Aspergillosis--and a 2161 misleading sensitivity result, Lancet, vol.370, p.102, 2007.

S. J. Howard, A. C. Pasqualotto, and M. J. Anderson, Major variations in aspergillus fumigatus 2163 arising within aspergillomas in chronic pulmonary aspergillosis, Mycoses, vol.56, pp.434-441, 2013.

W. W. Hope, M. Cuenca-estrella, C. Lass-florl, and A. Mc, , p.2165

, Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility T. Eucast 2166 technical note on voriconazole and aspergillus spp, vol.19, pp.278-280, 2013.

M. C. Arendrup, J. Meletiadis, and J. W. Mouton, Eucast technical note on isavuconazole 2168 breakpoints for aspergillus, itraconazole breakpoints for candida and updates for the 2169 antifungal susceptibility testing method documents, Clin Microbiol Infect, vol.22, pp.571-2170, 2016.

J. H. Rex, . Clinical, and L. S. Institute, Reference method for broth dilution antifungal susceptibility 2172 testing of filamentous fungi: Approved standard, 2008.

P. R. Burgel, M. T. Baixench, and M. Amsellem, High prevalence of azole-resistant aspergillus 2175 fumigatus in adults with cystic fibrosis exposed to itraconazole, Antimicrob Agents, p.2176

, Chemother, vol.56, pp.869-874, 2012.

R. Araujo and A. Espinel-ingroff, Comparison of assessment of oxygen consumption, etest, and clsi 2178 m38-a2 broth microdilution methods for evaluation of the susceptibility of aspergillus 2179 fumigatus to posaconazole, Antimicrob Agents Chemother, vol.53, pp.4921-4923, 2009.

S. Arikan, B. Sancak, S. Alp, G. Hascelik, and P. Mcnicholas, Comparative in vitro activities of 2181 posaconazole, voriconazole, itraconazole, and amphotericin b against aspergillus and 2182 rhizopus, and synergy testing for rhizopus, Medical mycology, vol.46, pp.567-573, 2008.

J. Guinea, T. Pelaez, S. Recio, M. Torres-narbona, and E. Bouza, In vitro antifungal activities of 2184 isavuconazole (bal4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, p.2185

, Antimicrob Agents Chemother, vol.2186, pp.1396-1400, 2008.

S. J. Howard, E. Harrison, P. Bowyer, J. Varga, and D. W. Denning, Cryptic species and azole resistance 159

C. Cordonnier, M. Mohty, and C. Faucher, Safety of a weekly high dose of liposomal 2367 amphotericin b for prophylaxis of invasive fungal infection in immunocompromised patients: 2368 Prophysome study, Int J Antimicrob Agents, vol.31, pp.135-141, 2008.

O. Penack, S. Schwartz, and P. Martus, Low-dose liposomal amphotericin b in the prevention 2370 of invasive fungal infections in patients with prolonged neutropenia: Results from a 2371 randomized, single-center trial, Ann Oncol, vol.17, pp.1306-1312, 2006.

L. Annino, A. Chierichini, and B. Anaclerico, Prospective phase ii single-center study of the 2373 safety of a single very high dose of liposomal amphotericin b for antifungal prophylaxis in 2374 patients with acute myeloid leukemia, Antimicrob Agents Chemother, vol.57, pp.2596-2602, 2013.

J. R. Wingard, S. L. Carter, and T. J. Walsh, Randomized, double-blind trial of fluconazole versus 2376 voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell 2377 transplantation, Blood, vol.116, pp.5111-5118, 2010.

O. A. Cornely, T. Leguay, and J. Maertens, Randomized comparison of liposomal amphotericin 2379 b versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia, J Antimicrob, p.2380

, Chemother, vol.72, pp.2359-2367, 2017.

J. R. Wingard, S. L. Carter, and T. J. Walsh, Randomized, double-blind trial of fluconazole versus 2382 voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell 2383 transplantation, Blood, vol.116, pp.5111-5118, 2010.

D. I. Marks, A. Pagliuca, and C. C. Kibbler, Voriconazole versus itraconazole for antifungal 2385 prophylaxis following allogeneic haematopoietic stem-cell transplantation, Br J Haematol, vol.2386, pp.318-327, 2011.

A. J. Ullmann, J. H. Lipton, and D. H. Vesole, Posaconazole or fluconazole for prophylaxis in severe 2388 graft-versus-host disease, N Engl J Med, vol.356, pp.335-347, 2007.

D. J. Winston, R. T. Maziarz, and P. H. Chandrasekar, Intravenous and oral itraconazole versus 2390 intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic 2391 hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Annals of 2392 internal medicine, vol.138, pp.705-713, 2003.

K. A. Marr, W. Leisenring, and F. Crippa, Cyclophosphamide metabolism is affected by azole 2394 antifungals, Blood, vol.103, pp.1557-1559, 2004.

F. Menichetti, D. Favero, A. Martino, and P. , Itraconazole oral solution as prophylaxis for 2396 fungal infections in neutropenic patients with hematologic malignancies: A randomized, 2397 placebo-controlled, double-blind, multicenter trial. Gimema infection program. Gruppo 2398 italiano malattie ematologiche dell' adulto, Clin Infect Dis, vol.28, pp.250-255, 1999.

H. G. Prentice, D. Caillot, B. Dupont, F. Menichetti, and U. Schuler, Oral and intravenous itraconazole 2400 for systemic fungal infections in neutropenic haematological patients

. London, Acta Haematol, vol.101, pp.56-62, 1998.

J. L. Harousseau, A. W. Dekker, and A. Stamatoullas-bastard, Itraconazole oral solution for 2403 primary prophylaxis of fungal infections in patients with hematological malignancy and 2404 profound neutropenia: A randomized, double-blind, double-placebo, multicenter trial 2405 comparing itraconazole and amphotericin b, Antimicrob Agents Chemother, vol.44, pp.1887-2406, 2000.

J. I. Gallin, D. W. Alling, and H. L. Malech, Itraconazole to prevent fungal infections in chronic 2408 granulomatous disease, N Engl J Med, vol.348, pp.2416-2422, 2003.

L. De-repentigny, J. Ratelle, and J. M. Leclerc, Repeated-dose pharmacokinetics of an oral 2410 solution of itraconazole in infants and children, Antimicrob Agents Chemother, vol.42, pp.404-2411, 1998.

A. H. Groll, L. Wood, and M. Roden, Safety, pharmacokinetics, and pharmacodynamics of 2413 cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis, Antimicrob 2414 Agents Chemother, vol.46, pp.2554-2563, 2002.

A. B. Foot, P. A. Veys, and B. E. Gibson, Itraconazole oral solution as antifungal prophylaxis in children 2416 undergoing stem cell transplantation or intensive chemotherapy for haematological 2417 disorders, Bone Marrow Transplant, vol.24, pp.1089-1093, 1999.

A. Simon, M. Besuden, and S. Vezmar, Itraconazole prophylaxis in pediatric cancer patients 2419 receiving conventional chemotherapy or autologous stem cell transplants. Support Care 2420 Cancer, vol.15, pp.213-220, 2007.

M. R. Ananda-rajah, A. Grigg, and M. T. Downey, Comparative clinical effectiveness of 2422 prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute 2423 myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-2424 year period, Haematologica, vol.97, pp.459-463, 2012.

M. R. Ananda-rajah, A. Grigg, and M. A. Slavin, Making sense of posaconazole therapeutic drug 2426 monitoring: A practical approach, Curr Opin Infect Dis, vol.25, pp.605-611, 2012.

G. Krishna, M. Martinho, P. Chandrasekar, A. J. Ullmann, and H. Patino, Pharmacokinetics of oral 2428 posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-2429 host disease, Pharmacotherapy, vol.27, pp.1627-1636, 2007.

M. E. Welzen, R. J. Bruggemann, . Van-den, and J. M. Berg, A twice daily posaconazole dosing 2431 algorithm for children with chronic granulomatous disease, Pediatr Infect Dis J, vol.30, pp.2432-794, 2011.

M. Döring, C. Müller, and P. D. Johann, Analysis of posaconazole as oral antifungal prophylaxis 2434 in pediatric patients under 12 years of age following allogeneic stem cell transplantation, BMC Infect Dis, vol.12, p.263, 2012.

T. Lehrnbecher, A. Attarbaschi, and M. Duerken, Posaconazole salvage treatment in paediatric 2437 patients: A multicentre survey, Eur J Clin Microbiol Infect Dis, vol.29, pp.1043-1045, 2010.

K. Vanstraelen, A. Colita, and A. M. Bica, Pharmacokinetics of posaconazole oral suspension in 2439 children dosed according to body surface area, Pediatr Infect Dis J, vol.35, pp.183-188, 2016.

G. N. Mattiuzzi, J. Cortes, and G. Alvarado, Efficacy and safety of intravenous voriconazole and 2441 intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous 2442 leukemia or high-risk myelodysplastic syndrome, Support Care Cancer, vol.19, pp.19-26, 2011.

J. N. Barreto, C. L. Beach, and R. C. Wolf, The incidence of invasive fungal infections in 2444 neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary 2445 antifungal prophylaxis with voriconazole, Am J Hematol, vol.88, pp.283-288, 2013.

T. J. Walsh, M. O. Karlsson, and T. Driscoll, Pharmacokinetics and safety of intravenous 2447 voriconazole in children after single-or multiple-dose administration, Antimicrob Agents, p.2448

, Chemother, vol.48, pp.2166-2172, 2004.

M. O. Karlsson, I. Lutsar, and P. A. Milligan, Population pharmacokinetic analysis of voriconazole 2450 plasma concentration data from pediatric studies, Antimicrob Agents Chemother, vol.53, pp.2451-935, 2009.

T. A. Driscoll, H. Frangoul, and E. R. Nemecek, Comparison of pharmacokinetics and safety of 2453 voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy 2454 adults, Antimicrob Agents Chemother, vol.55, pp.5780-5789, 2011.

T. A. Driscoll, L. C. Yu, and H. Frangoul, Comparison of pharmacokinetics and safety of 2456 voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults

, Antimicrob Agents Chemother, vol.55, pp.5770-5779, 2011.

J. R. Molina, J. Serrano, and J. Sanchez-garcia, Voriconazole as primary antifungal prophylaxis 2459 in children undergoing allo-sct, Bone Marrow Transplant, vol.47, pp.562-567, 2012.

J. Tollemar, O. Ringden, and S. Andersson, Prophylactic use of liposomal amphotericin b 2461 (ambisome) against fungal infections: A randomized trial in bone marrow transplant 2462 recipients, Transplant Proc, vol.25, pp.1495-1497, 1993.

J. Tollemar, O. Ringden, S. Andersson, B. Sundberg, P. Ljungman et al., Randomized double-2464 blind study of liposomal amphotericin b (ambisome) prophylaxis of invasive fungal infections 2465 in bone marrow transplant recipients, Bone Marrow Transplant, vol.12, pp.577-582, 1993.

S. M. Kelsey, J. M. Goldman, and S. Mccann, Liposomal amphotericin (ambisome) in the 2467 prophylaxis of fungal infections in neutropenic patients: A randomised, double-blind, 2468 placebo-controlled study, Bone Marrow Transplant, vol.23, pp.163-168, 1999.

Y. Hong, P. J. Shaw, and C. E. Nath, Population pharmacokinetics of liposomal amphotericin b in 2470 pediatric patients with malignant diseases, Antimicrob Agents Chemother, vol.50, pp.935-942, 2006.

O. Ringden, F. Meunier, and J. Tollemar, Efficacy of amphotericin b encapsulated in liposomes 2472 (ambisome) in the treatment of invasive fungal infections in immunocompromised patients, p.2473

, Antimicrob Chemother, vol.28, pp.73-82, 1991.

H. Kolve, E. Ahlke, W. Fegeler, J. Ritter, H. Jurgens et al., Safety, tolerance and outcome of 2475 treatment with liposomal amphotericin b in paediatric patients with cancer or undergoing 2476 haematopoietic stem cell transplantation, J Antimicrob Chemother, vol.64, pp.383-387, 2009.

X. Huang, H. Chen, and M. Han, Multicenter, randomized, open-label study comparing the 2478 efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal 2479 infections in patients undergoing hematopoietic stem cell transplant, Biology of blood and 163 marrow transplantation : journal of the American Society for Blood and Marrow, p.2481

, Transplantation, vol.18, pp.1509-1516, 2012.

N. L. Seibel, C. Schwartz, and A. Arrieta, Safety, tolerability, and pharmacokinetics of 2483 micafungin (fk463) in febrile neutropenic pediatric patients, Antimicrob Agents Chemother, vol.2484, pp.3317-3324, 2005.

W. W. Hope, N. L. Seibel, and C. L. Schwartz, Population pharmacokinetics of micafungin in 2486 pediatric patients and implications for antifungal dosing, Antimicrob Agents Chemother, vol.2487, pp.3714-3719, 2007.

A. C. Arrieta, P. Maddison, and A. H. Groll, Safety of micafungin in pediatric clinical trials. Pediatr 2489, Infect Dis J, vol.30, pp.97-102, 2011.

P. A. Mehta, A. A. Vinks, and A. Filipovich, Alternate-day micafungin antifungal prophylaxis in 2491 pediatric patients undergoing hematopoietic stem cell transplantation: A pharmacokinetic 2492 study. Biology of blood and marrow transplantation : journal of the American Society for 2493 Blood and Marrow Transplantation, vol.16, pp.1458-1462, 2010.

J. Beaute, G. Obenga, L. Mignot, and L. , Epidemiology and outcome of invasive fungal diseases 2495 in patients with chronic granulomatous disease: A multicenter study in france, Pediatr Infect, p.2496

J. Dis, , vol.30, pp.57-62, 2011.

R. Mouy, F. Veber, and S. Blanche, Long-term itraconazole prophylaxis against aspergillus 2498 infections in thirty-two patients with chronic granulomatous disease, J Pediatr, vol.125, pp.2499-998, 1994.

J. Fortun, P. Martin-davila, and M. A. Sanchez, Voriconazole in the treatment of invasive mold 2501 infections in transplant recipients, Eur J Clin Microbiol Infect Dis, vol.22, pp.408-413, 2003.

T. Wieland, A. Liebold, M. Jagiello, G. Retzl, and D. E. Birnbaum, Superiority of voriconazole over 2503 amphotericin b in the treatment of invasive aspergillosis after heart transplantation, J Heart 2504 Lung Transplant, vol.24, pp.102-104, 2005.

M. Veroux, D. Corona, and M. Gagliano, Voriconazole in the treatment of invasive 2506 aspergillosis in kidney transplant recipients, Transplant Proc, vol.39, pp.1838-1840, 2007.

T. J. Walsh, T. Driscoll, and P. A. Milligan, Pharmacokinetics, safety, and tolerability of 2508 voriconazole in immunocompromised children, Antimicrob Agents Chemother, vol.54, pp.2509-4116, 2010.

E. H. Doby, D. K. Benjamin, J. Blaschke, and A. J. , Therapeutic monitoring of voriconazole in 2511 children less than three years of age: A case report and summary of voriconazole 2512 concentrations for ten children, Pediatr Infect Dis J, vol.31, pp.632-635, 2012.

P. Soler-palacin, M. A. Frick, and A. Martin-nalda, Voriconazole drug monitoring in the 2514 management of invasive fungal infection in immunocompromised children: A prospective 2515 study, J Antimicrob Chemother, vol.67, pp.700-706, 2012.

I. H. Bartelink, T. Wolfs, and M. Jonker, Highly variable plasma concentrations of voriconazole 2517 in pediatric hematopoietic stem cell transplantation patients, Antimicrob Agents Chemother. 2518, vol.57, pp.235-240, 2013.

R. N. Kotwani, P. C. Gokhale, P. V. Bodhe, B. G. Kirodian, N. A. Kshirsagar et al., A comparative 2520 study of plasma concentrations of liposomal amphotericin b (l-amp-lrc-1) in adults, children 2521 and neonates, Int J Pharm, vol.238, pp.11-15, 2002.

K. Bochennek, L. Tramsen, and N. Schedler, Liposomal amphotericin b twice weekly as 2523 antifungal prophylaxis in paediatric haematological malignancy patients, Clin Microbiol 2524 Infect, vol.17, pp.1868-1874, 2011.

A. H. Groll, G. Silling, and C. Young, Randomized comparison of safety and pharmacokinetics of 2526 caspofungin, liposomal amphotericin b, and the combination of both in allogeneic 2527 hematopoietic stem cell recipients, Antimicrob Agents Chemother, vol.54, pp.4143-4149, 2010.

K. Sunakawa, I. Tsukimoto, and Y. Tsunematsu, Evaluation of the safety and efficacy of 2529 liposomal amphotericin b (l-amb) in children, J Infect Chemother, vol.18, pp.456-465, 2012.

R. Herbrecht, J. Maertens, and L. Baila, Caspofungin first-line therapy for invasive aspergillosis 2531 in allogeneic hematopoietic stem cell transplant patients: An european organisation for 2532 research and treatment of cancer study, Bone Marrow Transplant, vol.45, pp.1227-1233, 2010.

C. Viscoli, R. Herbrecht, and H. Akan, An eortc phase ii study of caspofungin as first-line 2534 therapy of invasive aspergillosis in haematological patients, J Antimicrob Chemother, vol.64, pp.1274-1281, 2009.

O. A. Cornely, J. J. Vehreschild, and M. J. Vehreschild, Phase ii dose escalation study of 2537 caspofungin for invasive aspergillosis, Antimicrob Agents Chemother, vol.55, pp.5798-5803, 2011.

J. Groetzner, I. Kaczmarek, and T. Wittwer, Caspofungin as first-line therapy for the treatment 2539 of invasive aspergillosis after thoracic organ transplantation, J Heart Lung Transplant, vol.27, pp.1-6, 2008.

M. Winkler, J. Pratschke, and U. Schulz, Caspofungin for post solid organ transplant invasive 2542 fungal disease: Results of a retrospective observational study, Transpl Infect Dis, vol.12, pp.2543-230, 2010.

T. J. Walsh, P. C. Adamson, and N. L. Seibel, Pharmacokinetics, safety, and tolerability of 2545 caspofungin in children and adolescents, Antimicrob Agents Chemother, vol.49, p.4545, 2005.

M. Neely, H. S. Jafri, and N. Seibel, Pharmacokinetics and safety of caspofungin in older infants 2548 and toddlers, Antimicrob Agents Chemother, vol.53, pp.1450-1456, 2009.

S. Cesaro, M. Giacchino, and F. Locatelli, Safety and efficacy of a caspofungin-based 2550 combination therapy for treatment of proven or probable aspergillosis in pediatric 2551 hematological patients, BMC Infect Dis, vol.7, p.28, 2007.

T. Zaoutis, T. Lehrnbecher, and A. H. Groll, Safety experience with caspofungin in pediatric 2553 patients, Pediatr Infect Dis J, vol.28, pp.1132-1135, 2009.

T. E. Zaoutis, H. S. Jafri, and L. M. Huang, A prospective, multicenter study of caspofungin for the 2555 treatment of documented candida or aspergillus infections in pediatric patients, Pediatrics, vol.2556, pp.877-884, 2009.

A. L. Ngai, M. R. Bourque, R. J. Lupinacci, K. M. Strohmaier, and N. A. Kartsonis, Overview of safety 2558 experience with caspofungin in clinical trials conducted over the first 15 years: A brief report

, Int J Antimicrob Agents, vol.38, pp.540-544, 2011.

P. Manzoni, S. Rizzollo, and D. Farina, Response to "is liposomal amphotericin b really safety in 2561 neonates?, Early Hum Dev, vol.89, p.37, 2013.

E. Karadag-oncel, Y. Ozsurekci, M. Yurdakok, and A. Kara, Is liposomal amphotericin b really safety 2563 in neonates?, Early Hum Dev, vol.89, pp.35-36, 2013.

A. Scarcella, M. B. Pasquariello, B. Giugliano, M. Vendemmia, and A. De-lucia, Liposomal amphotericin 2565 b treatment for neonatal fungal infections, Pediatr Infect Dis J, vol.17, pp.146-148, 1998.

A. Juster-reicher, O. Flidel-rimon, M. Amitay, S. Even-tov, E. Shinwell et al., High-dose 2567 liposomal amphotericin b in the therapy of systemic candidiasis in neonates, Eur J Clin, p.2568

, Microbiol Infect Dis, vol.22, pp.603-607, 2003.

S. C. Mellinghoff, M. Bassetti, and D. Dorfel, Isavuconazole shortens the qtc interval, Mycoses, 2017.

O. A. Cornely and . Isavuconazole, J Antimicrob Chemother, vol.2572, pp.2-4, 2017.

D. Neofytos, D. Ostrander, and S. Shoham, Voriconazole therapeutic drug monitoring: Results 2574 of a prematurely discontinued randomized multicenter trial, Transpl Infect Dis, vol.17, pp.2575-831, 2015.

J. I. Ito, P. H. Chandrasekar, and R. Hooshmand-rad, Effectiveness of amphotericin b lipid complex 2577 (ablc) treatment in allogeneic hematopoietic cell transplant (hct) recipients with invasive 2578 aspergillosis (ia), Bone Marrow Transplant, vol.36, pp.873-877, 2005.

S. Kohno, T. Masaoka, and H. Yamaguchi, A multicenter, open-label clinical study of 2580 micafungin (fk463) in the treatment of deep-seated mycosis in japan, Scand J Infect Dis, vol.2581, pp.372-379, 2004.

D. W. Denning, K. A. Marr, and W. M. Lau, Micafungin (fk463), alone or in combination with other 2583 systemic antifungal agents, for the treatment of acute invasive aspergillosis, J Infect, vol.53, pp.337-349, 2006.

D. P. Kontoyiannis, V. Ratanatharathorn, and J. A. Young, Micafungin alone or in combination 2586 with other systemic antifungal therapies in hematopoietic stem cell transplant recipients 2587 with invasive aspergillosis, Transpl Infect Dis, vol.11, pp.89-93, 2009.

D. Caillot, A. Thiebaut, and R. Herbrecht, Liposomal amphotericin b in combination with 2589 caspofungin for invasive aspergillosis in patients with hematologic malignancies: A 2590 randomized pilot study (combistrat trial), Cancer, vol.110, pp.2740-2746, 2007.

F. Dohen-becue, F. Salez, and P. Ramon, Revue des maladies respiratoires, vol.15, pp.791-796, 1998.

S. Schwartz, M. Ruhnke, and P. Ribaud, Improved outcome in central nervous system 2594 aspergillosis, using voriconazole treatment, Blood, vol.106, pp.2641-2645, 2005.

T. K. Kourkoumpetis, A. Desalermos, M. Muhammed, and E. Mylonakis, Central nervous system 2596 aspergillosis: A series of 14 cases from a general hospital and review of 123 cases from the 2597 literature, Medicine (Baltimore), vol.91, pp.328-336, 2012.

M. J. Rüping, N. Albermann, and F. Ebinger, Posaconazole concentrations in the central 2599 nervous system, J Antimicrob Chemother, vol.62, pp.1468-1470, 2008.

J. M. Coleman, G. G. Hogg, J. V. Rosenfeld, and K. D. Waters, Invasive central nervous system 2601 aspergillosis: Cure with liposomal amphotericin b, itraconazole, and radical surgery--case 2602 report and review of the literature, Neurosurgery, vol.36, pp.858-863, 1995.

K. V. Clemons, M. Espiritu, R. Parmar, and D. A. Stevens, Comparative efficacies of conventional 2604 amphotericin b, liposomal amphotericin b (ambisome), caspofungin, micafungin, and 2605 voriconazole alone and in combination against experimental murine central nervous system 2606 aspergillosis, Antimicrob Agents Chemother, vol.49, pp.4867-4875, 2005.

M. Ellis, D. Spence, and B. De-pauw, An eortc international multicenter randomized trial (eortc 2608 number 19923) comparing two dosages of liposomal amphotericin b for treatment of 2609 invasive aspergillosis, Clin Infect Dis, vol.27, pp.1406-1412, 1998.

S. Schwartz, M. Ruhnke, P. Ribaud, E. Reed, P. Troke et al., Poor efficacy of amphotericin b-2611 based therapy in cns aspergillosis, Mycoses, vol.50, pp.196-200, 2007.

A. J. Ullmann, M. A. Sanz, and A. Tramarin, Prospective study of amphotericin b formulations in 2613 immunocompromised patients in 4 european countries, Clin Infect Dis, vol.43, pp.29-38, 2006.

J. R. Wingard, P. Kubilis, and L. Lee, Clinical significance of nephrotoxicity in patients treated 2615 with amphotericin b for suspected or proven aspergillosis, Clin Infect Dis, vol.29, pp.1402-2616, 1999.

C. Girmenia, G. Pizzarelli, E. Pozzi, G. Cimino, G. Gentile et al., Improving outcomes of 2618 acute invasive aspergillus rhinosinusitis in patients with hematologic malignancies or aplastic 2619 anemia: The role of voriconazole, Haematologica, vol.93, pp.159-160, 2008.

M. J. Thurtell, A. L. Chiu, and L. A. Goold, Neuro-ophthalmology of invasive fungal sinusitis: 14 2621 consecutive patients and a review of the literature, Clin Experiment Ophthalmol, vol.41, pp.2622-567, 2013.

A. Daudia and N. S. Jones, Advances in management of paranasal sinus aspergillosis, J Laryngol, p.2624

, Otol, vol.122, pp.331-335, 2008.

C. Cordonnier, M. Rovira, and J. Maertens, Voriconazole for secondary prophylaxis of invasive 2626 fungal infections in allogeneic stem cell transplant recipients: Results of the vosifi study

, Haematologica, vol.95, pp.1762-1768, 2010.

F. Liu, T. Wu, and J. B. Wang, Risk factors for recurrence of invasive fungal infection during 2629 secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients

, Transpl Infect Dis, vol.15, pp.243-250, 2013.

S. Gerlach, J. J. Vehreschild, M. Ruping, G. Fischer, and O. A. Cornely, At the university hospital of cologne: Molecular typing of environmental and clinical 2633 isolates, Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerichen 2634 GHO, 2008.

K. Allinson, H. Kolve, H. G. Gumbinger, H. J. Vormoor, K. Ehlert et al., Secondary antifungal 2636 prophylaxis in paediatric allogeneic haematopoietic stem cell recipients, J Antimicrob, p.2637

. Chemother, , vol.61, pp.734-742, 2008.

P. De-fabritiis, A. Spagnoli, D. Bartolomeo, and P. , Efficacy of caspofungin as secondary 2639 prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary 2640 and/or systemic fungal infection, Bone Marrow Transplant, vol.40, pp.245-249, 2007.

R. Martino, R. Parody, and T. Fukuda, Impact of the intensity of the pretransplantation 2642 conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic 2643 hematopoietic stem cell transplantation: A retrospective survey of the infectious diseases 2644 working party of the european group for blood and marrow transplantation, Blood, vol.108, pp.2928-2936, 2006.

W. H. Kruger, B. Russmann, and M. De-wit, Haemopoietic cell transplantation of patients with 2647 a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin 2648 b, Acta Haematol, vol.113, pp.104-108, 2005.

A. Nosari, M. Ravini, and R. Cairoli, Surgical resection of persistent pulmonary fungus nodules 2650 and secondary prophylaxis are effective in preventing fungal relapse in patients receiving 2651 chemotherapy or bone marrow transplantation for leukemia, Bone Marrow Transplant, vol.2652, pp.631-635, 2007.

R. Eliashar, I. B. Resnick, A. Goldfarb, J. Wohlgelernter, and M. Gross, Endoscopic surgery for sinonasal 2654 invasive aspergillosis in bone marrow transplantation patients. The Laryngoscope, vol.117, pp.2655-78, 2007.

S. Cesaro, G. Cecchetto, D. Corti, and F. , Results of a multicenter retrospective study of a 2657 combined medical and surgical approach to pulmonary aspergillosis in pediatric neutropenic 2658 patients, Pediatric blood & cancer, vol.49, pp.909-913, 2007.

P. Matt, F. Bernet, and J. Habicht, Predicting outcome after lung resection for invasive 2660 pulmonary aspergillosis in patients with neutropenia, Chest, vol.126, pp.1783-1788, 2004.

F. Reichenberger, J. Habicht, and A. Kaim, Lung resection for invasive pulmonary aspergillosis 2662 in neutropenic patients with hematologic diseases, Am J Respir Crit Care Med, vol.158, pp.2663-885, 1998.

M. Boogaerts, D. J. Winston, and E. J. Bow, Intravenous and oral itraconazole versus intravenous 2665 amphotericin b deoxycholate as empirical antifungal therapy for persistent fever in 2666 neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A 2667 randomized, controlled trial, Annals of internal medicine, vol.135, pp.412-422, 2001.

J. R. Wingard, M. H. White, and E. Anaissie, A randomized, double-blind comparative trial 2669 evaluating the safety of liposomal amphotericin b versus amphotericin b lipid complex in the 2670 empirical treatment of febrile neutropenia. L amph/ablc collaborative study group, Clin Infect, p.2671

, Dis, vol.31, pp.1155-1163, 2000.

M. H. White, R. A. Bowden, and E. S. Sandler, Randomized, double-blind clinical trial of 2673 amphotericin b colloidal dispersion vs. Amphotericin b in the empirical treatment of fever 2674 and neutropenia, Clin Infect Dis, vol.27, pp.296-302, 1998.

K. Tamura, A. Urabe, and M. Yoshida, Efficacy and safety of micafungin, an echinocandin 2676 antifungal agent, on invasive fungal infections in patients with hematological disorders, Lymphoma, vol.50, pp.92-100, 2009.

C. Lass-florl, Triazole antifungal agents in invasive fungal infections: A comparative review

, Drugs, vol.71, pp.2405-2419, 2011.

K. A. Marr, M. Boeckh, R. A. Carter, H. W. Kim, and L. Corey, Combination antifungal therapy for invasive 2681 aspergillosis, Clin Infect Dis, vol.39, pp.797-802, 2004.

J. R. Perfect, K. A. Marr, and T. J. Walsh, Voriconazole treatment for less-common, emerging, or 2683 refractory fungal infections, Clin Infect Dis, vol.36, pp.1122-1131, 2003.

L. R. Baden, J. T. Katz, and J. A. Fishman, Salvage therapy with voriconazole for invasive fungal 2685 infections in patients failing or intolerant to standard antifungal therapy, Transplantation, vol.2686, pp.1632-1637, 2003.

A. Candoni, R. Mestroni, and D. Damiani, Caspofungin as first line therapy of pulmonary 2688 invasive fungal infections in 32 immunocompromised patients with hematologic 2689 malignancies, Eur J Haematol, vol.75, pp.227-233, 2005.

T. T. Ng and D. W. Denning, Liposomal amphotericin b (ambisome) therapy in invasive fungal 2691 infections. Evaluation of united kingdom compassionate use data. Archives of internal 2692 medicine, vol.155, pp.1093-1098, 1995.

R. Y. Hachem, M. R. Boktour, and H. A. Hanna, Amphotericin b lipid complex versus liposomal 2694 amphotericin b monotherapy for invasive aspergillosis in patients with hematologic 2695 malignancy, Cancer, vol.112, pp.1282-1287, 2008.

T. J. Walsh, J. W. Hiemenz, and N. L. Seibel, Amphotericin b lipid complex for invasive fungal 2697 infections: Analysis of safety and efficacy in 556 cases, Clin Infect Dis, vol.26, pp.1383-1396, 1998.

P. H. Chandrasekar and J. I. Ito, Amphotericin b lipid complex in the management of invasive 2699 aspergillosis in immunocompromised patients, Clin Infect Dis, vol.40, issue.6, pp.392-400, 2005.

B. A. Oppenheim, R. Herbrecht, and S. Kusne, The safety and efficacy of amphotericin b colloidal 2701 dispersion in the treatment of invasive mycoses, Clin Infect Dis, vol.21, pp.1145-1153, 1995.

R. Herbrecht, V. Letscher, A. E. Cavalier, and A. , Safety and efficacy of amphotericin b colloidal 2703 dispersion. An overview, Chemotherapy, vol.45, issue.1, pp.67-76, 1999.

R. Betts, A. Glasmacher, and J. Maertens, Efficacy of caspofungin against invasive candida or 2705 invasive aspergillus infections in neutropenic patients, Cancer, vol.106, pp.466-473, 2006.

G. Egerer, D. Reichert, M. W. Pletz, P. Kaskel, K. J. Krobot et al., Caspofungin for treatment 2707 of invasive aspergillosis in germany: Results of a pre-planned subanalysis of an international 2708 registry, Eur J Med Res, vol.17, p.7, 2012.

J. W. Hiemenz, . Raad, . Ii, and J. A. Maertens, Efficacy of caspofungin as salvage therapy for 2710 invasive aspergillosis compared to standard therapy in a historical cohort, Eur J Clin Microbiol, vol.29, pp.1387-1394, 2010.

N. A. Kartsonis, A. J. Saah, J. Lipka, C. Taylor, A. F. Sable et al., Salvage therapy with caspofungin for 2713 invasive aspergillosis: Results from the caspofungin compassionate use study, J Infect, vol.50, pp.196-205, 2005.

C. O. Morrissey, M. A. Slavin, and M. A. O'reilly, Caspofungin as salvage monotherapy for invasive 2716 aspergillosis in patients with haematological malignancies or following allogeneic stem cell 2717 transplantation: Efficacy and concomitant cyclosporin a, Mycoses, vol.50, issue.1, pp.24-37, 2007.

J. Maertens, G. Egerer, and W. S. Shin, Caspofungin use in daily clinical practice for treatment 2719 of invasive aspergillosis: Results of a prospective observational registry, BMC Infect Dis, vol.10, p.182, 2010.

L. Ubeda-iglesias, A. Loza-vazquez, and A. , Efficacy and safety of caspofungin in 2722 critically ill patients. Procas study, Rev Esp Quimioter, vol.25, pp.274-282, 2012.

D. A. Enoch, S. F. Idris, S. H. Aliyu, C. Micallef, O. Sule et al., Micafungin for the treatment of 2724 invasive aspergillosis, J Infect, vol.68, pp.507-526, 2014.

R. Y. Hachem, A. A. Langston, and J. R. Graybill, Posaconazole as salvage treatment of invasive 2726 fungal infections in patients with underlying renal impairment, J Antimicrob Chemother, vol.2727, pp.1386-1391, 2008.

W. J. Heinz, G. Egerer, H. Lellek, A. Boehme, and J. Greiner, Posaconazole after previous antifungal 2729 therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective 2730 analysis, Mycoses, vol.56, pp.304-310, 2013.

D. Caillot, Intravenous itraconazole followed by oral itraconazole for the treatment of 2732 amphotericin-b-refractory invasive pulmonary aspergillosis, Acta Haematol, vol.109, p.111, 2003.

M. L. Luong, C. Chaparro, and A. Stephenson, Pretransplant aspergillus colonization of cystic 2735 fibrosis patients and the incidence of post-lung

, Transplantation, vol.97, pp.351-357, 2014.

V. Monforte, A. Roman, and J. Gavalda, Nebulized amphotericin b prophylaxis for aspergillus 2738 infection in lung transplantation: Study of risk factors, J Heart Lung Transplant, vol.20, pp.2739-1274, 2001.

M. Iversen, C. M. Burton, and S. Vand, Aspergillus infection in lung transplant patients: 2741 Incidence and prognosis, Eur J Clin Microbiol Infect Dis, vol.26, pp.879-886, 2007.

J. L. Hsu, M. A. Khan, and R. A. Sobel, Aspergillus fumigatus invasion increases with progressive 2743 airway ischemia, PLoS One, vol.8, p.77136, 2013.

A. Sole, P. Morant, M. Salavert, J. Peman, P. Morales et al., Aspergillus 2745 infections in lung transplant recipients: Risk factors and outcome, Clin Microbiol Infect, vol.11, pp.359-365, 2005.

L. A. Danziger-isakov, S. Worley, and S. Arrigain, Increased mortality after pulmonary fungal 2748 infection within the first year after pediatric lung transplantation, J Heart Lung Transplant, vol.2749, pp.655-661, 2008.

E. Sarmiento, J. J. Rodriguez-molina, and J. Fernandez-yanez, Igg monitoring to identify the risk 2751 for development of infection in heart transplant recipients, Transpl Infect Dis, vol.8, pp.49-53, 2006.

L. A. Collins, M. H. Samore, and M. S. Roberts, Risk factors for invasive fungal infections 2753 complicating orthotopic liver transplantation. The Journal of infectious diseases, vol.170, pp.2754-644, 1994.

N. Singh, S. Husain, and P. Astidco, Invasive aspergillosis in solid organ transplant recipients

, Am J Transplant, vol.9, issue.4, pp.180-191, 2009.

N. Singh, T. L. Pruett, and S. Houston, Invasive aspergillosis in the recipients of liver 2758 retransplantation, Liver Transpl, vol.12, pp.1205-1209, 2006.

F. Saliba, V. Delvart, and P. Ichai, Fungal infections after liver transplantation: Outcomes and 2760 risk factors revisited in the meld era, Clin Transplant, vol.27, pp.454-461, 2013.

H. He, L. Ding, F. Li, and Q. Zhan, Clinical features of invasive bronchial-pulmonary aspergillosis in 2762 critically ill patients with chronic obstructive respiratory diseases: A prospective study, Crit 2763 Care, vol.15, p.5, 2011.

P. Bulpa, A. Dive, and Y. Sibille, Invasive pulmonary aspergillosis in patients with chronic obstructive 2765 pulmonary disease, Eur Respir J, vol.30, pp.782-800, 2007.

T. Kistemann, H. Huneburg, M. Exner, V. Vacata, and S. Engelhart, Role of increased environmental 2767 aspergillus exposure for patients with chronic obstructive pulmonary disease (copd) treated 2768 with corticosteroids in an intensive care unit, Int J Hyg Environ Health, vol.204, pp.347-351, 2002.

C. K. Murray, F. L. Loo, and D. R. Hospenthal, Incidence of systemic fungal infection and related 2770 mortality following severe burns, Burns, vol.34, pp.1108-1112, 2008.

T. Lahmer, M. Messer, and C. Schwerdtfeger, Invasive mycosis in medical intensive care unit 2772 patients with severe alcoholic hepatitis, Mycopathologia, vol.177, pp.193-197, 2014.

J. Ballard, L. Edelman, and J. Saffle, Positive fungal cultures in burn patients: A multicenter 2774 review, J Burn Care Res, vol.29, pp.213-221, 2008.

E. E. Horvath, C. K. Murray, and G. M. Vaughan, Fungal wound infection (not colonization) is 2776 independently associated with mortality in burn patients, Annals of surgery, vol.245, pp.978-2777, 2007.

J. Guinea, J. Jensen, and T. Pelaez, Value of a single galactomannan determination (platelia), p.2779

, for the diagnosis of invasive aspergillosis in non-hematological patients with clinical isolation 2780 of aspergillus spp, Medical mycology, vol.46, pp.575-579, 2008.

J. Acosta, M. Catalan, and A. Del-palacio-perez-medel, Prospective study in critically ill non-2782 neutropenic patients: Diagnostic potential of (1,3)-beta-d-glucan assay and circulating 2783 galactomannan for the diagnosis of invasive fungal disease, Eur J Clin Microbiol Infect Dis, vol.2784, pp.721-731, 2012.

H. He, L. Ding, B. Sun, F. Li, and Q. Zhan, Role of galactomannan determinations in bronchoalveolar 2786 lavage fluid samples from critically ill patients with chronic obstructive pulmonary disease for 2787 the diagnosis of invasive pulmonary aspergillosis: A prospective study, Crit Care, vol.16, p.2788, 2012.

F. Khorvash, M. Meidani, L. Babaei, S. Abbasi, B. Ataei et al., Galactomannan antigen assay 2790 from bronchoalveolar lavage fluid in diagnosis of invasive pulmonary aspergillosis in 2791 intensive care units patients, Adv Biomed Res, vol.3, p.68, 2014.

J. Steinmann, J. Buer, and P. M. Rath, Detection of aspergillus fumigatus in blood samples from 2793 critically ill patients in intensive care units by use of the septifast assay, Journal of clinical 2794 microbiology, vol.54, pp.1918-1921, 2016.

H. Westh, G. Lisby, and F. Breysse, Multiplex real-time pcr and blood culture for identification 2796 of bloodstream pathogens in patients with suspected sepsis, Clin Microbiol Infect, vol.15, pp.2797-544, 2009.

C. J. Clancy, R. A. Jaber, and H. L. Leather, Bronchoalveolar lavage galactomannan in diagnosis of 2799 invasive pulmonary aspergillosis among solid-organ transplant recipients, vol.45, pp.1759-1765, 2007.

F. F. Gazzoni, B. Hochhegger, and L. C. Severo, High-resolution computed tomographic findings 2802 of aspergillus infection in lung transplant patients, Eur J Radiol, vol.83, pp.79-83, 2014.

M. Hoenigl, C. Koidl, and W. Duettmann, Bronchoalveolar lavage lateral-flow device test for 2804 invasive pulmonary aspergillosis diagnosis in haematological malignancy and solid organ 2805 transplant patients, J Infect, vol.65, pp.588-591, 2012.

B. D. Alexander, P. B. Smith, R. D. Davis, J. R. Perfect, and L. B. Reller, The (1,3){beta}-d-glucan test as an 2807 aid to early diagnosis of invasive fungal infections following lung transplantation, Journal of 2808 clinical microbiology, vol.48, pp.4083-4088, 2010.

S. Husain, E. J. Kwak, and A. Obman, Prospective assessment of platelia aspergillus 2810 galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant 2811 recipients, Am J Transplant, vol.4, pp.796-802, 2004.

S. Husain, D. L. Paterson, and S. M. Studer, Aspergillus galactomannan antigen in the 2813 bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant 2814 recipients, Transplantation, vol.83, pp.1330-1336, 2007.

J. Ambrosioni, S. Coll, and C. Manzardo, Voriconazole and cobicistat-boosted antiretroviral 2816 salvage regimen co-administration to treat invasive aspergillosis in an hiv-infected patient, p.2817

, Antimicrob Chemother, vol.71, pp.1125-1127, 2016.

R. Utili, R. Zampino, D. Vivo, and F. , Improved outcome of pulmonary aspergillosis in heart 2819 transplant recipients with early diagnosis and itraconazole treatment, Clin Transplant, vol.14, pp.282-286, 2000.

S. Husain, B. Capitano, and T. Corcoran, Intrapulmonary disposition of amphotericin b after 2822 aerosolized delivery of amphotericin b lipid complex (abelcet; ablc) in lung transplant 2823 recipients, Transplantation, vol.90, pp.1215-1219, 2010.

K. Mucha, B. Foroncewicz, and T. Orlowski, Atypical presentation of invasive pulmonary 2825 aspergillosis in a liver transplant recipient, Ann Transplant, vol.18, pp.238-242, 2013.

F. Lopez-medrano, M. Fernandez-ruiz, and J. T. Silva, Clinical presentation and determinants of 2827 mortality of invasive pulmonary aspergillosis in kidney transplant recipients: A multinational 2828 cohort study, Am J Transplant, vol.16, pp.3220-3234, 2016.

M. Kleinberg, Aspergillosis in the clear outcomes trial: Working toward a real-world clinical 2830 perspective, Medical mycology, vol.43, issue.1, pp.289-294, 2005.

P. K. Linden, K. Coley, P. Fontes, J. J. Fung, and S. Kusne, Invasive aspergillosis in liver transplant 2832 recipients: Outcome comparison of therapy with amphotericin b lipid complex and a 2833 historical cohort treated with conventional amphotericin b, Clin Infect Dis, vol.37, pp.17-25, 2003.

J. Walter, I. Sobottka, X. Rogiers, D. Broering, and L. Fischer, Invasive aspergillosis caused by 2835 aspergillus terreus in a living donor liver transplant recipient successfully treated by 2836 caspofungin, Mycoses, vol.54, pp.220-222, 2011.

M. Aguilar-guisado, J. Givalda, and P. Ussetti, Pneumonia after lung transplantation in the 2838 resitra cohort: A multicenter prospective study, Am J Transplant, vol.7, pp.1989-1996, 2007.

C. F. Neoh, G. I. Snell, and B. Levvey, Preemptive treatment with voriconazole in lung transplant 2840 recipients, Transpl Infect Dis, vol.15, pp.344-353, 2013.

R. H. Drew, D. Ashley, E. Benjamin, D. K. , J. et al.,

, Comparative safety of amphotericin b lipid complex and amphotericin b deoxycholate as 2843 aerosolized antifungal prophylaxis in lung-transplant recipients, Transplantation, vol.77, pp.2844-232, 2004.

V. Monforte, P. Ussetti, and J. Gavalda, Feasibility, tolerability, and outcomes of nebulized 2846 liposomal amphotericin b for aspergillus infection prevention in lung transplantation, J Heart 2847 Lung Transplant, vol.29, pp.523-530, 2010.

V. Monforte, A. Lopez-sanchez, and F. Zurbano, Prophylaxis with nebulized liposomal 2849 amphotericin b for aspergillus infection in lung transplant patients does not cause changes in 2850 the lipid content of pulmonary surfactant, J Heart Lung Transplant, vol.32, pp.313-319, 2013.

J. M. Borro, A. Sole, and M. De-la-torre, Efficiency and safety of inhaled amphotericin b lipid 2852 complex (abelcet) in the prophylaxis of invasive fungal infections following lung 2853 transplantation, Transplant Proc, vol.40, pp.3090-3093, 2008.

K. Williams, M. Mansh, P. Chin-hong, J. Singer, and A. St, Voriconazole-associated cutaneous 2855 malignancy: A literature review on photocarcinogenesis in organ transplant recipients, Infect Dis, vol.58, pp.997-1002, 2014.

J. G. Montoya, S. V. Chaparro, and D. Celis, Invasive aspergillosis in the setting of cardiac 2858 transplantation, Clin Infect Dis, vol.37, issue.3, pp.281-292, 2003.

P. Martin, M. J. , M. Rivas, R. , B. Caballero et al., Efficacy and tolerance of 2860 different types of prophylaxis for prevention of early aspergillosis after heart transplantation

, Transplant Proc, vol.42, pp.3014-3016, 2010.

N. Singh, D. L. Paterson, T. Gayowski, M. M. Wagener, and I. R. Marino, Preemptive prophylaxis with a 2863 lipid preparation of amphotericin b for invasive fungal infections in liver transplant recipients 2864 requiring renal replacement therapy, Transplantation, vol.71, pp.910-913, 2001.

J. F. Castroagudin, C. Ponton, and M. Bustamante, Prospective interventional study to evaluate 2866 the efficacy and safety of liposomal amphotericin b as prophylaxis of fungal infections in 2867 high-risk liver transplant recipients, Transplant Proc, vol.37, pp.3965-3967, 2005.

A. Reed, J. B. Herndon, and N. Ersoz, Effect of prophylaxis on fungal infection and costs for 2869 high-risk liver transplant recipients, Liver Transpl, vol.13, pp.1743-1750, 2007.

J. Fortun, P. Martin-davila, and M. Montejo, Prophylaxis with caspofungin for invasive fungal 2871 infections in high-risk liver transplant recipients, Transplantation, vol.87, pp.424-435, 2009.

A. Chakrabarti, S. Sethi, D. S. Raman, and D. Behera, Eight-year study of allergic bronchopulmonary 2873 aspergillosis in an indian teaching hospital, Mycoses, vol.45, pp.295-299, 2002.

T. Tashiro, K. Izumikawa, and M. Tashiro, A case series of chronic necrotizing pulmonary 2875 aspergillosis and a new proposal, Jpn J Infect Dis, vol.66, pp.312-316, 2013.

B. Dupont, Itraconazole therapy in aspergillosis: Study in 49 patients, J Am Acad Dermatol, vol.2877, pp.607-614, 1990.

H. Sambatakou, B. Dupont, H. Lode, and D. W. Denning, Voriconazole treatment for subacute 2879 invasive and chronic pulmonary aspergillosis. The American journal of medicine, vol.119, pp.2880-527, 2006.

T. Saito, S. Fujiuchi, and Y. Tao, Efficacy and safety of voriconazole in the treatment of chronic 2882 pulmonary aspergillosis: Experience in japan, Infection, vol.40, pp.661-667, 2012.

T. W. Felton, C. Baxter, C. B. Moore, S. A. Roberts, W. W. Hope et al., Efficacy and safety of 2884 posaconazole for chronic pulmonary aspergillosis, Clin Infect Dis, vol.51, pp.1383-1391, 2010.

A. Astellas, . Basilea, . Bayer, D. Cidara, and . University, NIH UM1AI104681), vol.2, p.2888

L. University, M. Matinas, . Company, . Medpace, . Melinta et al., , p.2889

R. Rempex and S. Pasteur, Scynexis, Seres, is a consultant to Amplyx, p.2890

D. Cidara, . Volterra, . F2g, . Gilead, . Janssen et al., , p.2891

S. Seres, Tetraphase, Vical, and received lecture honoraria from Astellas, p.2892

/. Merck and P. Msd, Ader has nothing to disclose. Dr. Aguado 2893 received honoraria for speaking at symposia organised on behalf of Pfizer, Merck Sharp & Dohme 2894 (MSD), Schering-Plough and Gilead and was on advisory boards for antifungal agents on, p.2895

A. Msd, G. Pfizer, and . Dr, Arikan-Akdagli reports non-financial support from Pfizer, outside the submitted 2898 work. Dr. Barnes reports personal fees from Gilead, Basilia and Biomerieux, grants from EORTC, 2899 outside the submitted work. Dr. Beigelman-Aubry reports personal fees from Gilead, outside the 2900 submitted work. Dr. Blot reports grants from Pfizer, outside the submitted work. Dr. Bouza has 2901 nothing to disclose. Dr. Brüggemann has received grants and consultancy fees as well as speaker 2902 fees from MSD, Pfizer, Gilead and Astellas. All contracts were with Radboudumc and all payments 2903 have been received by Radboudumc. Dr. Buchheidt reports personal fees and non-financial support 2904 from Astellas, Akova has nothing to disclose. Dr. Arendrup reports personal 2896 fees from MSD and Pfizer, grants from Basilea, Gilead, Amplyx, F2G and Cidara, outside the 2897 submitted work. Dr, p.2905

. Gliead, Dohme/Merck, grants, 2906 personal fees and non-financial support from Pfizer, outside the submitted work. Dr. Cadranel 2907 reports personal fees from MSD, outside the submitted work. Dr. Castagnola reports personal fees 2908 from Astellas Pharma, non-financial support from Gilead, outside the submitted work

, Chakrabarti has nothing to disclose. Dr. Cuenca-Estrella reports grants and other from Gilead and 2910

. Msd and C. Amplyx, Scynexis and F2G, other from Astellas, outside the submitted 2911 work. Dr. Denning and family hold Founder shares in F2G Ltd, a University of Manchester spin, p.179

, antifungal discovery company. He acts or has recently acted as a consultant to Astellas, p.2913

. Basilea, . Scynexis, . Cidara, . Biosergen, . Quintiles et al., the last 3 years, 2914 he has been paid for talks on behalf of Astellas, Dynamiker, Gilead, Merck and Pfizer. He is a 2915 longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, p.2916

, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines 2917 group and the British Society for Medical Mycology Standards of Care committee

, Denning has a patent Assays for Fungal Infection licensed. Dr. Dimopoulos has nothing to disclose

. Dr, Fortún has nothing to disclose. Dr. Gangneux reports grants and personal fees from Pfizer, MSD, p.2920

, Gilead and Astellas during the conduct of the study. Dr. Garbino has nothing to disclose. Dr. Groll 2921 reports grants and personal fees from Gilead, Merck, Sharp & Dohme and Pfizer, p.2922

B. Astellas, Heinz reports personal fees from Astellas, p.2923

B. Gilead, MSD Sharp & Dohme / Merck and Pfizer, outside 2924 the submitted work. Dr. Herbrecht reports personal fees from Astellas, p.2925

, Pfizer, outside the submitted work. Dr. Heussel reports personal fees from Boehringer Ingelheim, p.2926

G. Novartis, . Intermune, . Fresenius, P. Siemens, B. Ingelheim et al., , 2927.

, Lungs licensed. Dr. Kibbler reports personal fees from Gilead, outside the submitted work

, Klimko reports personal fees from Astellas and Pfizer, and grants and personal fees from Merck, 2931 outside the submitted work, Dr. Kullberg reports personal fees from Astellas, p.2932

S. Pfizer, Lagrou reports grants, personal fees and non-2933 financial support from MSD, Pfizer and Gilead, personal fees from Abbott, outside the submitted 2934 work. Dr. Lange reports personal fees from Chiesi, p.2935

N. Lucane, T. , and T. , outside the submitted work. Dr. Lass-Flörl reports 2936 grants, personal fees and other from Astellas Pharma and Gilead, p.2937

;. Pfizer and B. Dohme,

, Lehrnbecher reports grants, personal fees and non-financial support from Gilead Sciences, personal 2939 fees and non-financial support from Astellas and Merck/MSD, personal fees from Basilea, outside 2940 the submitted work. Dr. Lewis reports personal fees from Gilead, p.2941

, Merck, personal fees from Cidara, outside the submitted work. Dr. Loeffler has nothing to disclose

. Dr, Pfizer and Gilead, personal fees and non-financial support from Basilea 2944 and F2G, personal fees from Scynexis, during the conduct of the study. Dr. Marchetti has nothing to 2945 disclose. Dr. Meis reports personal fees and grants for consultancy from Astellas, MSD and Scynexis, 2946 grants from F2G and Pulmozyme, personal fees and grands for lectures including service on speakers 2947 bureaus from Merck, Gilead and TEVA, grants for travel and accommodation from Nordic-Pharma, 2948 outside the submitted work. Dr. Muñoz has nothing to disclose. Dr. Pagano reports grants and 2949 personal fees from Gilead, personal fees from MSD, Pfizer, Novartis, Janssen and Basilea, outside 2950 the submitted work, Lotholary has nothing to disclose. Dr. Maertens reports grants, personal fees and non-financial 2943 support from MSD, Astellas, p.2951

, Associates of Cape Cod, personal fees from Gilead and MSD, other from Gilead, during the conduct 2952 of the study. Dr. Roilides reports grants, personal fees and non-financial support from Astellas, p.2953

G. Merck and . Pfizer, Ruhnke reports personal fees from Basilea 2954 and Scynexis for board membership, personal fees from Basilea and Janssen for lectures including 2955 service on speakers bureaus, personal fees from Janssen for development of educational 2956 presentation, outside the submitted work. Dr. Sanguinetti has nothing to disclose. Dr. Sheppard 2957 reports grants and personal fees from Merck, outside the submitted work. Dr. Sinko reports 2958 personal fees (honoraria, fees for consulting, lectures, speakers bureaus) from Pfizer, p.2959

. Astellas and . Dr, Skiada has nothing to disclose. Dr. Ullmann reports personal fees from Pfizer, Astellas, p.2960

G. Msd, Vehreschild reports personal fees, non-financial 2961 support and other from Astellas, during the conduct of the study, p.2962

M. Astellas and . Msd, grants from Seres Therapeutics and DaVolterra, grants and personal fees 2963 from Gilead, personal fees from Berlin Chemie, Falk Foundation, Organobalance and Pfizer, outside 181 the submitted work. Dr. Verweij reports grants from Gilead Sciences, MSD and F2G, outside the 2965 submitted work. Dr. Viscoli reports personal fees from MSD, p.2966

. Basilea, outside the submitted work. Dr. Warris reports grants from Gilead, p.2967

, Basilea, outside the submitted work